Do Hedge Funds Love Endocyte, Inc. (ECYT)?
Legendary investors such as Leon Cooperman and Seth Klarman earn enormous amounts of money for themselves and their investors by doing in-depth research on small-cap stocks that big brokerage houses don...
Endocyte Inc (ECYT)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | GLG Partners Noam Gottesman | 0 | $0 | 0% | |
| 2. | Acuta Capital Partners Manfred Yu | 0 | $0 | 0% | |
| 3. | Ghost Tree Capital Ken Greenberg And David Kim | 0 | $0 | 0% | |
| 4. | Schonfeld Strategic Advisors Ryan Tolkin (Cio) | 0 | $0 | 0% | |
| 5. | Great Point Partners Jeffrey Jay And David Kroin | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.84 | 5,600 | $27,104.00 | 288,605 | 2017-11-13 | Filing | |
| $3.52 | 11,375 | $40,040.00 | 217,981 | 2016-05-10 | Filing | |
| $2.79 | 10,000 | $27,900.00 | 200,999 | 2016-01-19 | Filing | |
| $2.80 | 20,000 | $56,000.00 | 190,999 | 2016-01-15 | Filing | |
| $3.16 | 1,589 | $5,021.24 | 33,944 | 2011-12-21 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $15.56 | 5,928 | $92,237.90 | 321,550 | 2018-10-05 | Filing | |
| $15.55 | 6,771 | $105,316.13 | 70,869 | 2018-10-05 | Filing | |
| $15.56 | 9,028 | $140,436.86 | 122,219 | 2018-10-05 | Filing | |
| $15.56 | 9,111 | $141,748.03 | 101,040 | 2018-10-05 | Filing | |
| $15.56 | 9,028 | $140,436.86 | 121,353 | 2018-10-05 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 0 | $0 | 0% | |
| 2. | 0 | $0 | 0% | |
| 3. | 0 | $0 | 0% |
News See All
How Endocyte, Inc. (ECYT) Stacks Up Against Its Peers
Hedge funds run by legendary names like Nelson Peltz and David Tepper make billions of dollars a year for themselves and their super-rich accredited investors (you’ve got to have a minimum of $1 million...
Why Are Insiders Bullish On These 3 Companies?
Most investors are awaiting a fundamental catalyst to diminish their concerns about the potential impact of a slowing global economy on the U.S economy and put a halt to the equities sell-off.
Hedge Funds Are Buying Endocyte, Inc. (ECYT)
World-class money managers like Bill Ackman and Barry Rosenstein only invest their wealthy clients' money after undertaking a rigorous examination of any potential stock.
Hedge Funds Are Crazy About Astex Pharmaceuticals, Inc. (ASTX)
In the 21st century investor’s toolkit, there are dozens of indicators shareholders can use to analyze publicly traded companies.
AstraZeneca plc (ADR) (AZN), Merck & Co., Inc. (MRK), Endocyte, Inc. (ECYT): Three Things You Need to Know About This Big Pharma Deal
Through the years, London-based drugmaker AstraZeneca plc (ADR) (NYSE:AZN) and U.S. pharmaceutical firm Merck & Co., Inc. (NYSE:MRK) have partnered on several occasions to develop drugs together.
What Hedge Funds Think About Kythera Biopharmaceuticals Inc (KYTH)
To the average investor, there are tons of methods market participants can use to track publicly traded companies. Two of the most useful are hedge fund and insider trading activity.
Hedge Funds Aren't Crazy About Rigel Pharmaceuticals, Inc. (RIGL) Anymore
In the eyes of many investors, hedge funds are seen as useless, outdated investment tools of a forgotten age.
Hedge Funds Are Buying Endocyte, Inc. (ECYT)
At the moment, there are plenty of metrics shareholders can use to watch Mr. Market. A pair of the best are hedge fund and insider trading activity.
Hedge Funds Are Betting On Kythera Biopharmaceuticals Inc (KYTH)
Kythera Biopharmaceuticals Inc (NASDAQ:KYTH) was in 10 hedge funds' portfolio at the end of March.
Billionaire Hedge Funds
